Abstract − To identify genes whose expression correlated with biological features of therapy-related AML (t-AML), we analyzed the expression profiles of de novo AML t(9;11) and t-AML t(9;11) bone marrow samples using previously published SAGE data. Three-hundred twenty-nine transcripts that satisfied statistical (P<0.05) and magnitude-of-change (≥ 4-fold) criteria were identified as differentially expressed between de novo AML t(9;11) and t-AML t(9;11) cells. Of these transcripts, 301 (91%) matched known genes or ESTs and were classified according to functional categories (http://david.abcc.ncifcrf.gov/). The majority of differentially expressed genes in t-AML t(9;11) were involved in the regulation of biological and metabolic processes. Especially prominent among these were genes related to immune and drug responses. These results establish a framework for developing new drugs for the treatment of t-AML.
INTRODUCTION
Therapy-related acute myeloid leukemia (t-AML) can develop in de novo AML or other malignant diseases after exposure to cytotoxic agents used to treat the disease, including radiation, drugs and other chemicals (Seedhouse and Russell, 2007) . t-AML, which constitutes approximately 10%-15% of all AML, is induced mainly by chromosomal aberrations, such as translocations, deletions and inversions (Rowley, 1999; Lee et al., 2006) . These include the t(15;17) and t(8;21) translocations, the inv(16) inversion, and rearrangements at the 11q23 locus, such as the t(9;11) translocation.
Compared with de novo AML, t-AML has a high frequency of atypical karyotypes (Kantarjian et al., 1986; Pedersen-Bjergaard et al., 1990) , which occur as a direct result of the action of alkylating agents, topoisomerase II inhibitors and radiation used as treatment modalities (Pedersen-Bjergaard et al., 2002) . Alkylating agents generate various chromosomal abnormalities by inducing DNA interstrand cross-linking (Hemminki and Kallama, 1986; Povirk and Shuker, 1994) , and topoisomerase II inhibitors produce aberrant chromosomes by interfering with the repair of damaged chromosomes (Seedhouse and Russell, 2007; Liu, 1989) . These karyotypic abnormalities have ramifications for whole-gene expression patterns, and the resulting disturbance in the normal function of myeloid cells is responsible for t-AML.
The death rate from t-AML is higher than of de novo AML, thus heightening the importance of accurately diagnosing and treating t-AML (Schoch et al., 2004) . This urgency is particularly acute with respect to leukemias of the 11q23 rearrangement type, which are an unfavorable group with a poor prognosis and high death rate relative to t(15;17), t(8;21) and inv(16) karyotypic leukemias (Schoch et al., 2004) . Currently, the diagnosis of leukemia is based on cytological and morphological properties of leukemic cells (Harris et al., 1999) . However, this process is time consuming and requires pathology expertise. To overcome this problem, recent efforts have focused on finding *Corresponding author Tel: +82-53-950-7363,Fax: +82-53-943-6925 E-mail: slee@knu.ac.kr molecular markers that can be used to distinguish various types of leukemia from one another (Valk et al., 2004; Haferlach et al., 2005) . Of the approaches available for identifying candidate molecular markers for leukemia, microarray techniques have been among the most widely used. In this study, we compared the gene expression profiles of de novo AML t(9;11) and t-AML t(9;11) cells using previously published AML SAGE data (Lee et al., 2006) . Our focus was on identifying factors that distinguish these two AML types with the ultimate goal of providing new insight into the etiology of AML.
MATERIALS AND METHODS
Acquisition of de novo AML t(9;11) and t-AML t(9;11) cell SAGE data
De novo AML t(9;11) and t-AML t(9;11) cells were compared using SAGE data obtained from the recent report by Lee et al (Lee et al., 2006) (http://www.ncbi.nlm.nih.gov/ projects/geo/, GEO accession #: GSE3255). The data from three individual de novo AML t(9;11) cells and three individual t-AML t(9;11) cells were integrated to create a profile of each cell type.
Bioinformatics and Statistical Analysis
SAGE tags were matched to a SAGEmap database updated on February 19, 2008 (http://www.ncbi.nlm.nih.gov/ SAGE/). For SAGE tags shared by multiple genes, only single-matched SAGE tags were selected. Genes that were differentially expressed between the de novo AML t(9;11) and t-AML t(9;11) cells were determined by analyzing SAGE data using IDEG6(http://telethon.bio.unipd.it/bioinfo/ IDEG6_form/). A general Chi-squared test (significance threshold = 0.05) was used to determine significance. Differentially expressed genes were defined as those for which P values were < 0.05 and the difference in expression between de novo AML t(9;11) and t-AML t(9;11) cells was ≥ 4-fold.
Functional Classification of differentially expressed genes
Genes that were differentially expressed between de novo AML t(9;11) and t-AML t(9;11) cells were functionally classified based on a Gene Ontology analysis using EASE (version 2.0) software (http://david.niaid.nih.gov/ david/ease.htm). EASE defines analyzed genes with respect to Biological Processes by performing a statistical analysis of gene categories in a gene list to identify those that are most overrepresented, either because of under-expression or over-expression.
RESULTS AND DISCUSSION

A comparison of gene expression profiles between de novo AML t(9;11) and t-AML t(9;11) cells
A total of 65,307 and 61,709 individual SAGE tags were selected from the de novo AML t(9;11) and t-AML t(9;11) cells, respectively, from which 36,465 and 28,723 unique SAGE tags were identified (Table. I). A comparison of the SAGE tags from t-AML t(9;11) cells with those from de novo AML t(9;11) cells showed that the patterns of gene expression in these two cell types were different, identifying 329 unique SAGE tags with P values < 0.05 and ≥ 4-fold differences in expression. Of these tags, 187 (57%) were increased and 142 (43%) were decreased in the t-AML t(9;11) cells; 301 (91%) were matched to the SAGE map database and 28 (9%) had no match (Table. II). Sixteen of the genes in the "increased" group had more than two SAGE tags and four in the "decreased" group had more than two tags. These 291 matched genes were classified using the DAVID functional annotation tool (http://david.abcc.ncifcrf.gov/).
Identification of genes differentially expressed in de novo AML t(9;11) and t-AML t(9;11) cells
Examples of genes that were differentially expressed between t-AML t(9;11) cells and de novo AML t(9;11) cells are presented in Table III . Among the overexpressed genes, NFKBIA is known to be a major oncogene in various malignant tumors and diseases (Srivastava and Anderson, 2007; Hatta et al., 2003) ; MPO protects DNA from oxygen radical-mediated damage during the maturation and differentiation of myeloid cells (Murao et al., 1988) ; RNF7 exerts an anti-apoptotic function against reactive oxygen species (ROS) generated by redox-reagents (Duan et al., 1999) ; TPT1 inhibits apoptosis induced by the antineoplastic agent, etoposide, used in the treatment of leukemia (Zhang et al., 2002) ; SIVA induces apoptosis through the caspase-dependent mitochondrial pathway (Py et al., 2004) ; PBEF1 delays neutrophil apoptosis by inhibiting the activity of caspase-8 and caspase-3 (Jia et al., 2004) ; and SNRPF, SNRPD2 and SNRPC have important roles in RNA splicing. Genes under-expressed in t-AML t(9;11) cells include EGR1, which is involved in cell growth and differentiation (Liu et al., 1996) ; HSPA1A, which is a member of the heat shock protein 70 family that regulates the cell cycle and proliferation (Rohde et al., 2005) ; JUND, which inhibits tumor angiogenesis by inhibiting RAS-associated ROS generation (Gerald et al., 2004) ; TSC22D3, which is a glucocorticoid-induced leucine zipper (GILZ) protein that controls the negative regulation of RAS-and RAFinduced cell proliferation (Ayroldi et al., 2007) ; and SH3GLB1, which regulates apoptosis induced by the proapoptotic gene, BAX (Cuddeback et al., 2001) . One of the most striking differences in expression between t-AML t(9;11) cells and de novo AML t(9;11) cells was MHC class I B, which was 100-fold over-expressed in t-AML cells. MHC class I B has important roles in immune responses mediated by natural killer cells and T cells. Despite the fact that MHC class I and class II serve similar functions, the expression of MHC class II genes was decreased in the t-AML t(9;11) cells. MHC class I and II are known to be involved in antigen presenting, but details of their functions are different. MHC class I regulates the activity of CD8+ T cells and natural killer cells, and MHC class II activates various immune cells by bind- ing to the T cell receptor of CD4+ T cells (Bierer and Burakoff, 1988) . Thus, by distinctly disrupting CD4+ and CD8+ T cell, and the natural killer cell functions and associated immune responses, differential expression of MHC class I and MHC class II between the de novo AML t(9;11) cells and t-AML t(9;11) cells can be expected to contribute to the differences in the symptoms between the two types of t(9;11) AML. These results indicate that, although de novo AML t(9;11) and t-AML t(9;11) have the same aberrant chromosome, their whole-gene expression patterns, and thus their symptoms, are different.
Functional clustering of the genes and differences in expression levels between t-AML t(9;11) de novo AML t(9;11) The 291 differentially expressed genes were classified using the DAVID functional annotation tool. Because one gene can have multiple functions, the gene count based on function is higher than the original number of genes. The genes in the "increased" group were mainly clustered into regulation of biological processes, macromolecule metabolic processes and primary metabolic processes, whereas most genes in the decreased group were related to primary metabolic processes and macromolecule metabolic processes (Table. IV). t-AML induced by cytotoxic agents, such as radiation and drugs used to treat leukemia and other malignancies, is a more lethal form of leukemia compared with de novo AML (Pedersen-Bjergaard et al., 1990; PedersenBjergaard et al., 2002; Hemminki and Kallama, 1986; Povirk and Shuker, 1994; Liu, 1989) . The major abnormal karyotypes are t(8;21), t(15;17) and inv (16), and the 11q23 rearrangements, which collectively account for approximately 40% of all AMLs (Licht, 2001) . The t(8;21), t(15;17) and inv(16) leukemia types are associated with a more favorable outcome, whereas the typical 11q23 rearrangement leukemia, t(9:11), is a high-risk leukemia type with more severe symptoms and a poor prognosis (Schoch et al., 2004) . Several interesting features were identified in this study. First, although de novo AML t(9;11) and t-AML t(9;11) have the same karyotype, the gene expression patterns of these leukemias are different. Second, a statistical analysis revealed that a few individual genes had striking statistical scores. In particular, MHC class I was increased 100-fold in the t-AML t(9;11) cells relative to de novo AML t(9;11) cells, whereas MHC class II, which has a similar function to that of MHC class I in the immune systems, was decreased. Third, the differences between the symptoms and prognosis of de novo AML t(9;11) and t-AML t(9;11) patients result from specific alterations in the biological pathways of each AML type. These alter- ations are manifested in several different aspects of cell function could be expected change various biological processes of the cells.
In conclusion, several genes with distinctive expression profiles were found in the de novo AML t(9;11) and t-AML t(9;11) SAGE datasets. Among these genes, MHC class I and MHC class II expression levels were significantly and substantially altered between de novo AML t(9;11) and t-AML t(9;11) cells. These distinct differences in MHC class I and MHC class II expression and their effects on biological pathways can be thus used to distinguish de novo AML t(9;11) from t-AML t(9;11). In addition, this data provides basic information that may help to elucidate the etiology of de novo AML t(9;11) and t-AML t(9;11) and contribute to the development of new treatments.
